Steroids in Fulminant Hepatitis A in the Pediatric Age Group

Fulminant Hepatic Failure Clinical Trial

Official title: Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group

Status Completed

Clinical Trial Summary

Fulminant hepatic failure (FHF) in children is a potentially devastating disease. The mortality rate may reach 80-90% in the absence of liver transplantation. Liver injury is considered to be mainly immune mediated with augmentation of cytolytic pathways of infected hepatocytes. For that, it is suggested that corticosteroids modulate the activity of the disease by suppressing the immune system.

Clinical Trial Description

Fulminant hepatic failure (FHF) in children is a potentially devastating disease. The mortality rate may reach 80-90% in the absence of liver transplantation. FHF is the clinical manifestation of liver cell death of a critical degree with insufficient hepatocellular regeneration and characterized by coagulopathy with or without hepatic encephalopathy.

Liver injury is considered to be mainly immune mediated with augmentation of cytolytic pathways of infected hepatocytes. For that, it was suggested that corticosteroids modulate the activity of the disease by suppressing the immune system. ;

Related Conditions & MeSH terms

• Fulminant Hepatic Failure
• Hepatic Insufficiency
• Hepatitis
• Hepatitis A
• Liver Failure
• Liver Failure, Acute

• NCT number: NCT02375867
• Study type: Interventional
• Source: National Liver Institute, Egypt
• Status: Completed
• Phase: Phase 4
• Start date: January 2015
• Completion date: September 2017